A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Public ClinicalTrials.gov record NCT04504916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.
Study identification
- NCT ID
- NCT04504916
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 102 participants
Conditions and interventions
Conditions
- Triple-negative Breast Cancer
- Non-squamous Non-small-cell Lung Cancer
- NSCLC
- Estrogen-receptor-positive Breast Cancer
- Progesterone-receptor-positive Breast Cancer
- Estrogen-receptor-negative Breast Cancer
- ER-negative Breast Cancer
- Progesterone-receptor Negative Breast Cancer
- PR-negative Breast Cancer
- HER2-negative Breast Cancer
- ER-positive Breast Cancer
- PR-positive Breast Cancer
- Platinum-resistant Ovarian Cancer
- Gastric Cancer
- Pancreatic Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2020 (Actual)
- Primary completion
- Jun 12, 2023 (Actual)
- Completion
- Jun 12, 2023 (Actual)
- Last update posted
- Nov 10, 2025
2020 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005) | Hollywood | Florida | 33021 | — |
| AdventHealth Orlando ( Site 0003) | Orlando | Florida | 32804 | — |
| Massachusetts General Hospital ( Site 0017) | Boston | Massachusetts | 02114 | — |
| John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002) | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0007) | New York | New York | 10021 | — |
| MD Anderson ( Site 0001) | Houston | Texas | 77030 | — |
| The University of Texas Health Science Center at San Antonio ( Site 0004) | San Antonio | Texas | 78229 | — |
| Swedish Medical Center ( Site 0008) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04504916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 10, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04504916 live on ClinicalTrials.gov.